Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with ...
June 12, 2013 - Science Daily
Inhalation Therapy for Lung Cancer Delivering chemotherapy through inhalation kills more cancer cells than traditional intravenous chemotherapy, according to a studies done at Rutgers University in New Jersey and at Oregon State University.
June 12, 2013 - ThirdAge
Breast cancer: PET and MR predict chemotherapy's ability to prolong life ( Society of Nuclear Medicine ) For patients with advanced breast cancer, positron emission tomography and magnetic resonance imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, say researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
June 11, 2013 - EurekAlert!